Braftovi (encorafenib)

News alerts, weekly reports and conference planners

Company:

Medison, Nerviano Medical Sciences, Ono Pharma, Pfizer, Pierre Fabre

Drug class:

BRAF inhibitor, cRAF inhibitor

Related drugs:

BRAF V600E	Colorectal Cancer	BRAF V600E	Colorectal Cancer	cetuximab + binimetinib + encorafenib Sensitive: A1 - Approval cetuximab + binimetinib + encorafenib Sensitive : A1	cetuximab + binimetinib + encorafenib Sensitive: A1 - Approval cetuximab + binimetinib + encorafenib Sensitive : A1
BRAF V600E	Colorectal Cancer	BRAF V600E	Colorectal Cancer	cetuximab + encorafenib Sensitive: A1 - Approval cetuximab + encorafenib Sensitive : A1	cetuximab + encorafenib Sensitive: A1 - Approval cetuximab + encorafenib Sensitive : A1
BRAF V600	Melanoma	BRAF V600	Melanoma	binimetinib + encorafenib Sensitive: A1 - Approval binimetinib + encorafenib Sensitive : A1	binimetinib + encorafenib Sensitive: A1 - Approval binimetinib + encorafenib Sensitive : A1
BRAF V600K	Melanoma	BRAF V600K	Melanoma	binimetinib + encorafenib Sensitive: A1 - Approval binimetinib + encorafenib Sensitive : A1	binimetinib + encorafenib Sensitive: A1 - Approval binimetinib + encorafenib Sensitive : A1
BRAF V600E	Melanoma	BRAF V600E	Melanoma	binimetinib + encorafenib Sensitive: A1 - Approval binimetinib + encorafenib Sensitive : A1	binimetinib + encorafenib Sensitive: A1 - Approval binimetinib + encorafenib Sensitive : A1
BRAF V600E	Non Small Cell Lung Cancer	BRAF V600E	Non Small Cell Lung Cancer	binimetinib + encorafenib Sensitive: A1 - Approval binimetinib + encorafenib Sensitive : A1	binimetinib + encorafenib Sensitive: A1 - Approval binimetinib + encorafenib Sensitive : A1
BRAF V600	Cutaneous Melanoma	BRAF V600	Cutaneous Melanoma	binimetinib + encorafenib Sensitive: A2 - Guideline binimetinib + encorafenib Sensitive : A2	binimetinib + encorafenib Sensitive: A2 - Guideline binimetinib + encorafenib Sensitive : A2
BRAF V600E	Colorectal Cancer	BRAF V600E	Colorectal Cancer	panitumumab + encorafenib Sensitive: A2 - Guideline panitumumab + encorafenib Sensitive : A2	panitumumab + encorafenib Sensitive: A2 - Guideline panitumumab + encorafenib Sensitive : A2
BRAF V600E	Cutaneous Melanoma	BRAF V600E	Cutaneous Melanoma	binimetinib + encorafenib Sensitive: A2 - Guideline binimetinib + encorafenib Sensitive : A2	binimetinib + encorafenib Sensitive: A2 - Guideline binimetinib + encorafenib Sensitive : A2
BRAF V600K	Cutaneous Melanoma	BRAF V600K	Cutaneous Melanoma	binimetinib + encorafenib Sensitive: A2 - Guideline binimetinib + encorafenib Sensitive : A2	binimetinib + encorafenib Sensitive: A2 - Guideline binimetinib + encorafenib Sensitive : A2
BRAF V600	Rectal Cancer	BRAF V600	Rectal Cancer	cetuximab + encorafenib Sensitive: A2 - Guideline cetuximab + encorafenib Sensitive : A2	cetuximab + encorafenib Sensitive: A2 - Guideline cetuximab + encorafenib Sensitive : A2
BRAF V600	Rectal Cancer	BRAF V600	Rectal Cancer	panitumumab + encorafenib Sensitive: A2 - Guideline panitumumab + encorafenib Sensitive : A2	panitumumab + encorafenib Sensitive: A2 - Guideline panitumumab + encorafenib Sensitive : A2
BRAF V600E	Colon Cancer	BRAF V600E	Colon Cancer	panitumumab + encorafenib Sensitive: A2 - Guideline panitumumab + encorafenib Sensitive : A2	panitumumab + encorafenib Sensitive: A2 - Guideline panitumumab + encorafenib Sensitive : A2
BRAF V600E	Colon Cancer	BRAF V600E	Colon Cancer	cetuximab + encorafenib Sensitive: A2 - Guideline cetuximab + encorafenib Sensitive : A2	cetuximab + encorafenib Sensitive: A2 - Guideline cetuximab + encorafenib Sensitive : A2
BRAF V600K	Melanoma	BRAF V600K	Melanoma	encorafenib Sensitive: B - Late Trials encorafenib Sensitive : B	encorafenib Sensitive: B - Late Trials encorafenib Sensitive : B
BRAF V600E	Melanoma	BRAF V600E	Melanoma	encorafenib Sensitive: B - Late Trials encorafenib Sensitive : B	encorafenib Sensitive: B - Late Trials encorafenib Sensitive : B
BRAF V600E	Colorectal Cancer	BRAF V600E	Colorectal Cancer	encorafenib Sensitive: B - Late Trials encorafenib Sensitive : B	encorafenib Sensitive: B - Late Trials encorafenib Sensitive : B
BRAF V600E	Colorectal Cancer	BRAF V600E	Colorectal Cancer	binimetinib + encorafenib Sensitive: B - Late Trials binimetinib + encorafenib Sensitive : B	binimetinib + encorafenib Sensitive: B - Late Trials binimetinib + encorafenib Sensitive : B
BRAF V600E + BRAF V600K	Melanoma	BRAF V600E + BRAF V600K	Melanoma	binimetinib + encorafenib Sensitive: B - Late Trials binimetinib + encorafenib Sensitive : B	binimetinib + encorafenib Sensitive: B - Late Trials binimetinib + encorafenib Sensitive : B
BRAF V600	Multiple Myeloma	BRAF V600	Multiple Myeloma	binimetinib + encorafenib Sensitive: C1 - Off-label binimetinib + encorafenib Sensitive : C1	binimetinib + encorafenib Sensitive: C1 - Off-label binimetinib + encorafenib Sensitive : C1
BRAF V600E	Ovarian Serous Adenocarcinoma	BRAF V600E	Ovarian Serous Adenocarcinoma	binimetinib + encorafenib Sensitive: C1 - Off-label binimetinib + encorafenib Sensitive : C1	binimetinib + encorafenib Sensitive: C1 - Off-label binimetinib + encorafenib Sensitive : C1
BRAF V600E	Pancreatic Cancer	BRAF V600E	Pancreatic Cancer	binimetinib + encorafenib Sensitive: C1 - Off-label binimetinib + encorafenib Sensitive : C1	binimetinib + encorafenib Sensitive: C1 - Off-label binimetinib + encorafenib Sensitive : C1
BRAF V600E	Solid Tumor	BRAF V600E	Solid Tumor	binimetinib + encorafenib Sensitive: C1 - Off-label binimetinib + encorafenib Sensitive : C1	binimetinib + encorafenib Sensitive: C1 - Off-label binimetinib + encorafenib Sensitive : C1
BRAF V600K	Solid Tumor	BRAF V600K	Solid Tumor	binimetinib + encorafenib Sensitive: C1 - Off-label binimetinib + encorafenib Sensitive : C1	binimetinib + encorafenib Sensitive: C1 - Off-label binimetinib + encorafenib Sensitive : C1
BRAF V600	Non Small Cell Lung Cancer	BRAF V600	Non Small Cell Lung Cancer	binimetinib + encorafenib Sensitive: C1 - Off-label binimetinib + encorafenib Sensitive : C1	binimetinib + encorafenib Sensitive: C1 - Off-label binimetinib + encorafenib Sensitive : C1
BRAF V600E	Neuroendocrine Tumor	BRAF V600E	Neuroendocrine Tumor	cetuximab + encorafenib Sensitive: C1 - Off-label cetuximab + encorafenib Sensitive : C1	cetuximab + encorafenib Sensitive: C1 - Off-label cetuximab + encorafenib Sensitive : C1
BRAF V600E	Glioma	BRAF V600E	Glioma	binimetinib + encorafenib Sensitive: C1 - Off-label binimetinib + encorafenib Sensitive : C1	binimetinib + encorafenib Sensitive: C1 - Off-label binimetinib + encorafenib Sensitive : C1
BRAF V600E	Glioblastoma	BRAF V600E	Glioblastoma	binimetinib + encorafenib Sensitive: C1 - Off-label binimetinib + encorafenib Sensitive : C1	binimetinib + encorafenib Sensitive: C1 - Off-label binimetinib + encorafenib Sensitive : C1
BRAF V600	Melanoma	BRAF V600	Melanoma	encorafenib Sensitive: C2 – Inclusion Criteria encorafenib Sensitive : C2	encorafenib Sensitive: C2 – Inclusion Criteria encorafenib Sensitive : C2
BRAF mutation	Melanoma	BRAF mutation	Melanoma	binimetinib + encorafenib Sensitive: C2 – Inclusion Criteria binimetinib + encorafenib Sensitive : C2	binimetinib + encorafenib Sensitive: C2 – Inclusion Criteria binimetinib + encorafenib Sensitive : C2
BRAF V600	Melanoma	BRAF V600	Melanoma	nivolumab + ipilimumab + binimetinib + encorafenib Sensitive: C2 – Inclusion Criteria nivolumab + ipilimumab + binimetinib + encorafenib Sensitive : C2	nivolumab + ipilimumab + binimetinib + encorafenib Sensitive: C2 – Inclusion Criteria nivolumab + ipilimumab + binimetinib + encorafenib Sensitive : C2
BRAF V600	Colorectal Cancer	BRAF V600	Colorectal Cancer	cetuximab + encorafenib Sensitive: C2 – Inclusion Criteria cetuximab + encorafenib Sensitive : C2	cetuximab + encorafenib Sensitive: C2 – Inclusion Criteria cetuximab + encorafenib Sensitive : C2

Braftovi (encorafenib)

Associations
(63)

Associations
(63)

Braftovi (encorafenib)

Associations(63)

Associations(63)

Associations
(63)

Associations
(63)